Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

"Right drug for the right patient": hurdles and the path forward in colorectal cancer.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting - 1 Jan 2013

Kopetz Scott

Abstract excerpt

Predictive biomarkers have been heralded as the way to develop the "right drug for the right patient." However, despite many studies incorporating novel biomarkers with targeted therapies, there has been little progress over the 5 years since the identification of KRAS mutations' ability to predi...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Biomarkers, Tumor
Share to Colorectal Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Molecular Diagnostic Techniques

Share to Molecular Targeted Therapy

Share to Patient Selection

Share to Precision Medicine

Share to Predictive Value of Tests

Source

Identifiers

PMID: 23714474
DOI: 10.14694/EdBook_AM.2013.33.e115

Genes

EGFR
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-23714474-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

"Right drug for the right patient": hurdles and the path forward in colorectal cancer.PMID 23714474Read ↗

Overview of predictive and prognostic biomarkers and their importance in developing a clinical pharmacology treatment plan in colorectal cancer patients.Semantic proximity Read ↗

Biomarker-based prediction of response to therapy for colorectal cancer: current perspective.Semantic proximity Read ↗

Predictive Biomarkers in Colorectal Cancer: From the Single Therapeutic Target to a Plethora of Options.Semantic proximity Read ↗

Prognostic and predictive molecular biomarkers in advanced colorectal cancer.Semantic proximity Read ↗

Agnostic Biomarkers and Molecular Signatures in Colorectal Cancer—Guiding Chemotherapy and Predicting ResponseSemantic proximity Read ↗

Biomarker in Colorectal Cancer.Semantic proximity Read ↗

Prognostic and Predictive Molecular Biomarkers for Colorectal Cancer: Updates and ChallengesSemantic proximity Read ↗

Molecular biomarkers of resistance to anti-EGFR treatment in metastatic colorectal cancer, from classical to innovationSemantic proximity Read ↗

Predictive and prognostic markers in the treatment of metastatic colorectal cancer (mCRC): personalized medicine at work.Semantic proximity Read ↗

An empirical review on the resistance mechanisms of epidermal growth factor receptor inhibitors and predictive molecular biomarkers in colorectal cancer.Semantic proximity Read ↗

Incorporating traditional and emerging biomarkers in the clinical management of metastatic colorectal cancer: an update.Semantic proximity Read ↗

Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.